Cefiderocol in the Treatment of Multidrug-resistant Gram-negative Bacilli Infections, a Retrospective Study

NCT05544682 | Unknown

• 1 other identifier: 8701
• Study Type: observational
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

Cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant Gram-negative bacilli. The circulation of bacterial strains multi-resistant to antibiotics is important at the Strasbourg University Hospital, so the investigators wish to report their local experience of the 1st uses of Cefiderocol in the treatment of infections with multi-resistant Gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)

Conditions

Multidrug Resistant Bacterial Infection

Keywords

Multidrug Resistant Bacterial Infections; Gram-negative bacilli infections; Cefiderocol; Antibiotics

Outcome Measures

Primary Outcomes (1)

• Retrospective evaluation of the therapeutic management of patients treated as part of routine care with Cefiderocol

  Survival, significant clinical improvement, absence of microbiological failure or infectious recurrence on day 30 after treatment with Céfiderocol

  30 days post treatment with Céfiderocol

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patient (≥18 years old) taken care of in the HUS and treated as part of routine care with Cefiderocol between 04/01/2020 and 08/31/2022.

You may qualify if:

• Adult patient (≥18 years old)
• taken care of in the HUS and treated as part of routine care with Cefiderocol between 04/01/2020 and 08/31/2022.
• Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.

You may not qualify if:

• \- Patient who has expressed his opposition to the retrospective reuse of his data for scientific research purposes.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service des maladies infectieuses et tropicales - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

Central Study Contacts

Yvon RUCH, MD

CONTACT

33 3 69 55 05 45; yvon.ruch@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 13, 2022
• First Posted: September 16, 2022
• Study Start: September 1, 2022
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: December 19, 2023

Record last verified: 2023-12

Locations

FR (1)